Foundation Medicine (FMI) Tops Q4 EPS by 12c, Offers FY Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/5/2026
- Dow jumps to record closing high after soft US jobs data, Nasdaq down with chip shares
- Goldman's Garrett sees investors dialing back tech exposure into H2
- AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
- Oil gains on short-covering buys ahead of US holiday
- Rivian stock jumps 5% on raised delivery outlook
Leerink Partners Reiterates Market perform After Foundation Medicine (FMI) Reports Weak 2016 Guidance
February 24, 2016 9:35 AM ESTLeerink Partners reiterated a Market Perform rating on Foundation Medicine (NASDAQ: FMI), and cut the price target to $15.00 (from $27.00), following the company's 4Q earnings report. FMI reported 4Q revenue of $26.1M, above the Street's $25.1M estimate. 2016 revenue guidance of $110M-$120M was ~10%/6% below consensus at... More
